Bluejay Diagnostics rises on completing sepsis test studies

Bluejay Diagnostics

06/07/2022 19:18

** Shares of Bluejay Diagnostics  BJDX.O  rise 6.5% to $1.14
in afternoon trade
    ** BJDX says it has completed its planned clinical studies
for its Symphony IL-6 Test, which is being developed to assess
the severity of sepsis or septic shock  urn:newsml:reuters.com:*:nGNX5tqbFV
    ** Sepsis is a potentially life-threatening condition that
occurs when the body's response to an infection damages its own
tissues
    ** Study completion is an important milestone towards
potentially filing a marketing application for the test with the
FDA by year-end - BJDX
    **  Symphony IL-6 test is BJDX's most advanced product
candidate and is designed to give results in about 20 minutes 
    ** Results of the studies will be published at an industry
meet being to be held from July 26 to July 28 - BJDX
    ** Stock has plunged 55.5% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))